Cynomolgus RANKL/OPGL/TNFSF11 (CD254) (Fc Tag) recombinant protein

Cynomolgus RANKL/OPGL/TNFSF11 (CD254) (Fc Tag) recombinant protein

• DataSheet
• Material Safety Data Sheets (MSDS)

Tumor necrosis factor ligand superfamily member 11, also known as Receptor activator of nuclear factor kappa-B ligand, Osteoprotegerin ligand, TNFSF11, RANKL, TRANCE, OPGL and CD254, is a single-pass type II membrane protein which belongs to the tumor necrosis factor family. The receptor activator of nuclear factor-kappaB ligand (RANKL), its cognate receptor RANK, and its natural decoy receptor osteoprotegerin have been identified as the final effector molecules of osteoclastic bone resorption. RANK and RANKL are key regulators of bone remodeling and regulate T cell/dendritic cell communications, and lymph node formation. Moreover, RANKL and RANK are expressed in mammary gland epithelial cells and control the development of a lactating mammary gland during pregnancy. Genetically, RANKL and RANK are essential for the development and activation of osteoclasts and bone loss in response to virtually all triggers tested. Inhibition of RANKL function via the natural decoy receptor osteoprotegerin (OPG, TNFRSF11B) prevents bone loss in postmenopausal osteoporosis and cancer metastases. Importantly, RANKL appears to be the pathogenetic principle that causes bone and cartilage destruction in arthritis. RANK-RANKL signaling not only activates a variety of downstream signaling pathways required for osteoclast development, but crosstalk with other signaling pathways also fine-tunes bone homeostasis both in normal physiology and disease. In addition, RANKL and RANK have essential roles in lymph node formation, establishment of the thymic microenvironment, and development of a lactating mammary gland during pregnancy.

Receptor activator of nuclear factor kappa-B ligand

OPGL; CD254; RANKL; ODF; SODF; RP11-86N24.2; HRANKL2; LY109L; TRANCE; OPG; OPTB2; TNFSF11

G7PW41

EGM_08438

Human Cells

A DNA sequence encoding the cynomolgus TNFSF11 (G7PW41) (Gly136-Asp317) was expressed with the Fc region of human IgG1 at the N-terminus.

Cynomolgus

The recombinant cynomolgus TNFSF11 comprises 442 amino acids and has a calculated molecular mass of 48.9 KDa. The apparent molecular mass of the protein is approximately 55 KDa in SDS-PAGE.

> 85 % as determined by SDS-PAGE

1. Immobilized Cynomolgus S4-Fc3L3-TNFSF11 at 10 μg/ml (100 μl/well) can bind biotinylated human TNFRSF11B-His (Cat:500115), The EC₅₀ of biotinylated human TNFRSF11B-His (Cat:500115) is 7.94-18.52 ng/ml.
2. The bioactivity of hRANKL was determined by measuring the ability of hRANKL to induce TRAP activity in Raw 264.7 cells. The ED₅₀ for this effect is typically 0.1-0.4 μg/mL.